Published in Clin Endocrinol (Oxf) on August 01, 1986
Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young Men. J Clin Invest (1997) 1.21
Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth. Proc Natl Acad Sci U S A (2009) 0.93
The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) (1977) 9.53
Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med (1994) 5.19
A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med (1998) 4.81
The DNA sequence and analysis of human chromosome 6. Nature (2003) 4.75
Radioimmunoassay of human serum thyrotrophin. Br Med J (1971) 4.59
Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infect Immun (1988) 4.44
Thyrotrophin-releasing hormone as a thyroid-function test. Lancet (1971) 4.34
Developmental and hormonally regulated messenger ribonucleic acid expression of KiSS-1 and its putative receptor, GPR54, in rat hypothalamus and potent luteinizing hormone-releasing activity of KiSS-1 peptide. Endocrinology (2004) 3.34
Grades of hypothyroidism. Br Med J (1973) 3.30
Vitiligo, thyroid disease and autoimmunity. Br J Dermatol (1968) 3.18
The thyrotrophin-releasing hormone test in diseases of the pituitary and hypothalamus. Lancet (1972) 3.10
Thyroid-stimulating immunoglobulins in Graves' disease. Lancet (1974) 2.84
Major surface antigen gene of a human malaria parasite cloned and expressed in bacteria. Nature (1984) 2.74
Circulating sensitised lymphocytes in Graves' disease. Observations on its pathogenesis. Lancet (1970) 2.73
Conducting clinical research in the new NHS: the model of cancer. United Kingdom Coordinating Committee on Cancer Research. BMJ (1994) 2.70
Hopping hotspots: global shifts in marine biodiversity. Science (2008) 2.68
Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone. Lancet (1974) 2.65
Carbimazole and the autoimmune response in Graves' disease. N Engl J Med (1980) 2.62
The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab (2001) 2.61
A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med (1994) 2.58
Relation of thyroid-stimulating immunoglobulins to thyroid function and effects of surgery, radioiodine, and antithyroid drugs. Lancet (1975) 2.57
Aggregative adherence fimbria II, a second fimbrial antigen mediating aggregative adherence in enteroaggregative Escherichia coli. Infect Immun (1997) 2.50
Bromocriptine therapy in acromegaly. Lancet (1975) 2.42
Cyclosporin improves Graves' ophthalmopathy. Lancet (1983) 2.32
Treatment of hypothyroidism: a reappraisal of thyroxine therapy. Br Med J (1973) 2.30
Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 2.25
Effects of KiSS-1 peptide, the natural ligand of GPR54, on follicle-stimulating hormone secretion in the rat. Endocrinology (2005) 2.23
Evaluating the performance of the Framingham risk equations in a population with diabetes. Diabet Med (2004) 2.20
OCULAR CHANGES ASSOCIATED WITH NAEVUS FLAMMEUS. Br J Ophthalmol (1939) 2.14
Estimating the prevalence of diagnosed diabetes in a health district of Wales: the importance of using primary and secondary care sources of ascertainment with adjustment for death and migration. Diabet Med (2000) 2.13
Hyponatraemia, hypothyroidism, and role of arginine-vasopressin. Lancet (1997) 2.11
GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults. Lancet (2000) 2.11
Advanced vaginal opening and precocious activation of the reproductive axis by KiSS-1 peptide, the endogenous ligand of GPR54. J Physiol (2004) 2.11
Molecular genetics of the genus Paracoccus: metabolically versatile bacteria with bioenergetic flexibility. Microbiol Mol Biol Rev (1998) 2.09
Antigens of the erythrocytes stages of the human malaria parasite Plasmodium falciparum detected by monoclonal antibodies. Mol Biochem Parasitol (1983) 2.00
Natural history of autoimmune thyroiditis. Br Med J (Clin Res Ed) (1981) 1.99
Characterization of the potent luteinizing hormone-releasing activity of KiSS-1 peptide, the natural ligand of GPR54. Endocrinology (2004) 1.97
Clinical pathology testing recommendations for nonclinical toxicity and safety studies. AACC-DACC/ASVCP Joint Task Force. Toxicol Pathol (1992) 1.94
Aggregative adherence fimbria I expression in enteroaggregative Escherichia coli requires two unlinked plasmid regions. Infect Immun (1993) 1.89
Association between postpartum thyroid dysfunction and thyroid antibodies and depression. BMJ (1992) 1.86
Letter: Complication of proximal gastric vagotomy. Br Med J (1974) 1.82
Trial of strategy for reducing the use of laboratory tests. Br Med J (Clin Res Ed) (1986) 1.82
Augmentation of central arterial pressure in mild primary hyperparathyroidism. J Clin Endocrinol Metab (2000) 1.82
Changes in hypothalamic KiSS-1 system and restoration of pubertal activation of the reproductive axis by kisspeptin in undernutrition. Endocrinology (2005) 1.81
Thyroid-stimulating hormone response to synthetic thyrotrophin releasing hormone in man. Br Med J (1970) 1.79
Effusions into body cavities in hypothyroidism. Lancet (1975) 1.77
Serum-thyrotropin levels after subtotal thyroidectomy for Graves' disease. Lancet (1971) 1.73
Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients. Lancet (1974) 1.71
Simple method of assessing splenic function in coeliac disease. Clin Sci (Lond) (1981) 1.70
Hyperinsulinaemia and microvascular angina ("syndrome X") Lancet (1991) 1.69
Action of growth-hormone-release inhibitory hormone in healthy men and in acromegaly. Lancet (1973) 1.68
Some patients don't need analgesics after surgery. J R Soc Med (1982) 1.68
Prediction of outcome in Graves' disease after carbimazole treatment. Q J Med (1986) 1.68
Dopamine agonists and pituitary tumor shrinkage. Endocr Rev (1992) 1.67
Luteinizing hormone and follicle stimulating hormone-releasing hormone test in patients with hypothalamic-pituitary-gonadal dysfunction. Br Med J (1973) 1.66
Walking track analysis: a long-term assessment of peripheral nerve recovery. Plast Reconstr Surg (1992) 1.65
Effects of bromocriptine on pituitary tumour size. Br Med J (1979) 1.64
Relationship between diabetes and mortality: a population study using record linkage. Diabetes Care (2000) 1.61
Interaction between secretion of the gonadotrophins, prolactin, growth hormone, thyrotrophin and corticosteroids in man: the effects of LH FSH-RH, TRH and hypoglycaemia alone and in combination. Clin Endocrinol (Oxf) (1973) 1.60
Meningococcal disease in Wales: clinical features, outcome and public health management. J Infect (1992) 1.60
Recommendations on the management of the asymptomatic patient with valvular heart disease. Eur Heart J (2002) 1.59
A systematic approach to erectile dysfunction in the cardiovascular patient: a Consensus Statement--update 2002. Int J Clin Pract (2002) 1.58
Presence of bovine leptin in edible commercial milk and infant formula. J Endocrinol Invest (2002) 1.56
Treatment of hyperthyroidism by radioactive iodine. Summary of a UK national survey prepared for the Royal College of Physicians Committee on Endocrinology and Diabetes. J R Coll Physicians Lond (1992) 1.56
Influence of thyroid status on serum immunoreactive leptin levels. J Clin Endocrinol Metab (1997) 1.55
A new player in cartilage homeostasis: adiponectin induces nitric oxide synthase type II and pro-inflammatory cytokines in chondrocytes. Osteoarthritis Cartilage (2008) 1.55
Thyroid-autoantibody synthesis by Hashimoto thyroid lymphocytes. Lancet (1979) 1.52
Ghrelin inhibits the proliferative activity of immature Leydig cells in vivo and regulates stem cell factor messenger ribonucleic acid expression in rat testis. Endocrinology (2004) 1.52
Ribosomal RNA sequences of Sarcocystis muris, Theileria annulata and Crypthecodinium cohnii reveal evolutionary relationships among apicomplexans, dinoflagellates, and ciliates. Mol Biochem Parasitol (1991) 1.51
A systematic approach to erectile dysfunction in the cardiovascular patient: a consensus statement. Int J Clin Pract (1999) 1.51
Confirming the drugs administered during anaesthesia: a feasibility study in the pilot National Health Service sites, UK. Br J Anaesth (2010) 1.50
Myopathy in acromegaly. Lancet (1970) 1.50
Serum leptin levels in normal children: relationship to age, gender, body mass index, pituitary-gonadal hormones, and pubertal stage. J Clin Endocrinol Metab (1997) 1.50
Towards a pro-inflammatory and immunomodulatory emerging role of leptin. Rheumatology (Oxford) (2006) 1.49
Lipid profiles and cardiovascular disease in the Whickham area with particular reference to thyroid failure. Clin Endocrinol (Oxf) (1977) 1.49
Smoking cessation: a consensus statement with special reference to primary care. Int J Clin Pract (2001) 1.48
Sequence analysis of subunits of the membrane-bound nitrate reductase from a denitrifying bacterium: the integral membrane subunit provides a prototype for the dihaem electron-carrying arm of a redox loop. Mol Microbiol (1995) 1.48
The immunoassay of thyroid-stimulating hormone and its clinical applications. Clin Endocrinol (Oxf) (1972) 1.47
Rapid microbiological assay for 5-fluorocytosine. Br Med J (1973) 1.47
Prolonged space flight-induced alterations in the structure and function of human skeletal muscle fibres. J Physiol (2010) 1.47
Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) (1980) 1.46
Ovarian ultrasonography highlights precision of symptoms of ovulation as markers of ovulation. Br Med J (Clin Res Ed) (1986) 1.45
Venous thrombo-embolism following inferior petrosal sinus sampling in Cushing's disease. J Endocrinol Invest (2000) 1.44
Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans. J Endocrinol Invest (2000) 1.44
Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. J Clin Endocrinol Metab (1993) 1.44
DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus. Virology (1998) 1.42
Hypothyroidism. Br Med J (1972) 1.41
Early-morning hyperglycemia in IDDM. Acute effects of cholinergic blockade. Diabetes Care (1989) 1.41
Body composition derived from whole body counting of potassium in growth hormone-deficient adults: a possible low intracellular potassium concentration. J Clin Endocrinol Metab (1996) 1.40
Novel signals for the integration of energy balance and reproduction. Mol Cell Endocrinol (2006) 1.40
Thyroid antibodies are produced by thyroid-derived lymphocytes. Clin Exp Immunol (1982) 1.39
Diagnostic dilemmas in Cushing's syndrome. Ann Clin Biochem (2000) 1.39
Hypopituitarism after coronary artery bypass grafting. BMJ (1998) 1.39
A single growth hormone (GH) determination is sufficient for the diagnosis of GH-deficiency in adult patients using the growth hormone releasing hormone plus growth hormone releasing peptide-6 test. Clin Endocrinol (Oxf) (2002) 1.39
Use of plaque assays to study thyroglobulin autoantibody synthesis by human peripheral blood lymphocytes. Scand J Immunol (1981) 1.39